Loading
SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
SNCAIP (Synphilin-1) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH.
No product in this corpus aims at SNCAIP yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SNCAIP: RNA tissue enhanced (cervix 16 nTPM, endometrium 1 18 nTPM, ovary 25 nTPM); blood lineage lineage enriched (granulocytes 8 nTPM); no normal tissue stained high; highest cancer staining colorectal cancer (5 of 10 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SNCAIP tissue; Open Targets ENSG00000064692 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Engelender et al, Nat. Genet, 1999, "Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions". Source.
Sources: HGNC HGNC:11139 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9Y6H5 (protein name, function text, keywords and locations (REST API)); CIViC gene SNCAIP (1 evidence items, 0 assertions, 1 variants; diseases: Medulloblastoma Non-WNT/non-SHH Group 4 (GraphQL API, CC0))
Isoform 2 inhibits the ubiquitin ligase activity of SIAH1 and inhibits proteasomal degradation of target proteins. Isoform 2 inhibits autoubiquitination and proteasomal degradation of SIAH1, and thereby increases cellular levels of SIAH. Isoform 2 modulates SNCA monoubiquitination by SIAH1. Location: Cytoplasm (UniProt). Locus 5q23.2 (HGNC).
RNA: tissue enhanced (cervix 16 nTPM, endometrium 1 18 nTPM, ovary 25 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 8 nTPM).
No normal tissue stained high.
Medium only: cervical cancer, endometrial cancer, glioma, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SNCAIP" OR ABSTRACT:"SNCAIP" OR TITLE:"synuclein alpha interacting protein" OR ABSTRACT:"synuclein alpha interacting protein" OR TITLE:"Synphilin-1" OR ABSTRACT:"Synphilin-1" OR TITLE:"SYPH1" OR ABSTRACT:"SYPH1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SNCAIP, not a curated reading list.